Current Hematologic Malignancy Reports

, Volume 8, Issue 1, pp 60–70 | Cite as

CARs in Chronic Lymphocytic Leukemia – Ready to Drive

  • Chitra Hosing
  • Partow Kebriaei
  • William Wierda
  • Bipulendu Jena
  • Laurence J. N. Cooper
  • Elizabeth Shpall
Chronic Leukemias (S O’Brien, Section Editor)

Abstract

Adoptive transfer of antigen-specific T cells has been adapted by investigators for treatment of chronic lymphocytic leukemia (CLL). To overcome issues of immune tolerance which limits the endogenous adaptive immune response to tumor-associated antigens (TAAs), robust systems for the genetic modification and characterization of T cells expressing chimeric antigen receptors (CARs) to redirect specificity have been produced. Refinements with regards to persistence and trafficking of the genetically modified T cells are underway to help improve potency. Clinical trials utilizing this technology demonstrate feasibility, and increasingly, these early-phase trials are demonstrating impressive anti-tumor effects, particularly for CLL patients, paving the way for multi-center trials to establish the efficacy of CAR+ T cell therapy.

Keywords

Chronic lymphocytic leukemia Chimeric antigen receptor Gene therapy 

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    • Dreger P, Dohner H, Ritgen M, et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial. Blood. 2010;116:2438–47. This is a prospective multicenter phase 2 study investigating the long-term outcome of reduced-intensity conditioning allogeneic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.PubMedCrossRefGoogle Scholar
  2. 2.
    Kharfan-Dabaja MA, Pidala J, Kumar A, et al. Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis. Bone Marrow Transplant. 2012.Google Scholar
  3. 3.
    Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26:4912–20.PubMedCrossRefGoogle Scholar
  4. 4.
    Khouri IF, Saliba RM, Admirand J, et al. Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia. Br J Haematol. 2007;137:355–63.PubMedCrossRefGoogle Scholar
  5. 5.
    Kolb HJ. Graft-versus-leukemia effects of transplantation and donor lymphocytes. Blood. 2008;112:4371–83.PubMedCrossRefGoogle Scholar
  6. 6.
    Cullis JO, Jiang YZ, Schwarer AP, et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 1992;79:1379–81.PubMedGoogle Scholar
  7. 7.
    Drobyski WR, Keever CA, Roth MS, et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood. 1993;82:2310–8.PubMedGoogle Scholar
  8. 8.
    Ferster A, Bujan W, Mouraux T, et al. Complete remission following donor leukocyte infusion in ALL relapsing after haploidentical bone marrow transplantation. Bone Marrow Transplant. 1994;14:331–2.PubMedGoogle Scholar
  9. 9.
    Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76:2462–5.PubMedGoogle Scholar
  10. 10.
    Lokhorst HM, Schattenberg A, Cornelissen JJ, et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation. Blood. 1997;90:4206–11.PubMedGoogle Scholar
  11. 11.
    Pati AR, Godder K, Lamb L, et al. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 1995;15:979–81.PubMedGoogle Scholar
  12. 12.
    Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361:478–88.PubMedCrossRefGoogle Scholar
  13. 13.
    Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer. 2005;5:263–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang J, Jensen M, Lin Y, et al. Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains. Hum Gene Ther. 2007;18:712–25.PubMedCrossRefGoogle Scholar
  15. 15.
    Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21:215–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Kowolik CM, Topp MS, Gonzalez S, et al. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. 2006;66:10995–1004.PubMedCrossRefGoogle Scholar
  17. 17.
    • Hudecek M, Schmitt TM, Baskar S, et al. The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor. Blood. 2010;116:4532–41. Study targeting the novel B-cell tumor associated antigen ROR 1 with chimeric antigen receptor expressing T-cells.PubMedCrossRefGoogle Scholar
  18. 18.
    Kahlon KS, Brown C, Cooper LJ, et al. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64:9160–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Imai C, Mihara K, Andreansky M, et al. Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia. 2004;18:676–84.PubMedCrossRefGoogle Scholar
  20. 20.
    Zhao Y, Wang QJ, Yang S, et al. A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol. 2009;183:5563–74.PubMedCrossRefGoogle Scholar
  21. 21.
    Letourneur F, Klausner RD. T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins. Proc Natl Acad Sci U S A. 1991;88:8905–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Yun CO, Nolan KF, Beecham EJ, et al. Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors. Neoplasia. 2000;2:449–59.PubMedCrossRefGoogle Scholar
  23. 23.
    Abken H, Hombach A, Heuser C. Immune response manipulation: recombinant immunoreceptors endow T-cells with predefined specificity. Curr Pharm Des. 2003;9:1992–2001.PubMedCrossRefGoogle Scholar
  24. 24.
    Yvon E, Del Vecchio M, Savoldo B, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15:5852–60.PubMedCrossRefGoogle Scholar
  25. 25.
    Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 16:1245–56.Google Scholar
  26. 26.
    Till BG, Jensen MC, Wang J, et al. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008;112:2261–71.PubMedCrossRefGoogle Scholar
  27. 27.
    Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825–33.PubMedGoogle Scholar
  28. 28.
    Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–70.PubMedCrossRefGoogle Scholar
  29. 29.
    Finney HM, Lawson AD, Bebbington CR, et al. Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product. J Immunol. 1998;161:2791–7.PubMedGoogle Scholar
  30. 30.
    Hombach A, Wieczarkowiecz A, Marquardt T, et al. Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 2001;167:6123–31.PubMedGoogle Scholar
  31. 31.
    Hombach A, Schneider C, Sent D, et al. An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells. Int J Cancer. 2000;88:115–20.PubMedCrossRefGoogle Scholar
  32. 32.
    June CH, Blazar BR, Riley JL. Engineering lymphocyte subsets: tools, trials and tribulations. Nat Rev Immunol. 2009;9:704–16.PubMedCrossRefGoogle Scholar
  33. 33.
    Jena B, Dotti G, Cooper LJ. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116:1035–44.Google Scholar
  34. 34.
    Rosenberg SA, Aebersold P, Cornetta K, et al. Gene transfer into humans–immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990;323:570–8.PubMedCrossRefGoogle Scholar
  35. 35.
    Rischer M, Pscherer S, Duwe S, et al. Human gammadelta T cells as mediators of chimaeric-receptor redirected anti-tumour immunity. Br J Haematol. 2004;126:583–92.PubMedCrossRefGoogle Scholar
  36. 36.
    Turatti F, Figini M, Alberti P, et al. Highly efficient redirected anti-tumor activity of human lymphocytes transduced with a completely human chimeric immune receptor. J Gene Med. 2005;7:158–70.PubMedCrossRefGoogle Scholar
  37. 37.
    Milone MC, Fish JD, Carpenito C, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17:1453–64.PubMedCrossRefGoogle Scholar
  38. 38.
    Naldini L, Blomer U, Gallay P, et al. In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 1996;272:263–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Varela-Rohena A, Carpenito C, Perez EE, et al. Genetic engineering of T cells for adoptive immunotherapy. Immunol Res. 2008;42:166–81.PubMedCrossRefGoogle Scholar
  40. 40.
    Singh H, Figliola MJ, Dawson MJ, et al. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies. Cancer Res. 2011;71:3516–27.PubMedCrossRefGoogle Scholar
  41. 41.
    Hu WS, Pathak VK. Design of retroviral vectors and helper cells for gene therapy. Pharmacol Rev. 2000;52:493–511.PubMedGoogle Scholar
  42. 42.
    Cavalieri S, Cazzaniga S, Geuna M, et al. Human T lymphocytes transduced by lentiviral vectors in the absence of TCR activation maintain an intact immune competence. Blood. 2003;102:497–505.PubMedCrossRefGoogle Scholar
  43. 43.
    Montini E, Cesana D, Schmidt M, et al. Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006;24:687–96.PubMedCrossRefGoogle Scholar
  44. 44.
    Newrzela S, Cornils K, Li Z, et al. Resistance of mature T cells to oncogene transformation. Blood. 2008;112:2278–86.PubMedCrossRefGoogle Scholar
  45. 45.
    Frantz S. Engineered T-cell therapy shows efficacy in blood cancer. Nat Biotechnol. 2011;29:853–5.PubMedCrossRefGoogle Scholar
  46. 46.
    Geurts AM, Yang Y, Clark KJ, et al. Gene transfer into genomes of human cells by the sleeping beauty transposon system. Mol Ther. 2003;8:108–17.PubMedCrossRefGoogle Scholar
  47. 47.
    Huang X, Guo H, Kang J, et al. Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies. Mol Ther. 2008;16:580–9.PubMedCrossRefGoogle Scholar
  48. 48.
    Jensen MC, Clarke P, Tan G, et al. Human T lymphocyte genetic modification with naked DNA. Mol Ther. 2000;1:49–55.PubMedCrossRefGoogle Scholar
  49. 49.
    Cooper LJ, Topp MS, Serrano LM, et al. T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. 2003;101:1637–44.PubMedCrossRefGoogle Scholar
  50. 50.
    Singh H, Manuri PR, Olivares S, et al. Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system. Cancer Res. 2008;68:2961–71.PubMedCrossRefGoogle Scholar
  51. 51.
    Xue X, Huang X, Nodland SE, et al. Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. Blood. 2009;114:1319–30.PubMedCrossRefGoogle Scholar
  52. 52.
    Manuri PV, Wilson MH, Maiti SN, et al. piggyBac transposon/transposase system to generate CD19-specific T cells for the treatment of B-lineage malignancies. Hum Gene Ther. 21:427–37.Google Scholar
  53. 53.
    Nakazawa Y, Huye LE, Dotti G, et al. Optimization of the PiggyBac transposon system for the sustained genetic modification of human T lymphocytes. J Immunother. 2009;32:826–36.PubMedCrossRefGoogle Scholar
  54. 54.
    Hackett PB, Ekker SC, Largaespada DA, et al. Sleeping beauty transposon-mediated gene therapy for prolonged expression. Adv Genet. 2005;54:189–232.PubMedCrossRefGoogle Scholar
  55. 55.
    Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc1-like transposon from fish, and its transposition in human cells. Cell. 1997;91:501–10.PubMedCrossRefGoogle Scholar
  56. 56.
    Izsvak Z, Chuah MK, Vandendriessche T, et al. Efficient stable gene transfer into human cells by the Sleeping Beauty transposon vectors. Methods. 2009;49:287–97.PubMedCrossRefGoogle Scholar
  57. 57.
    Hackett PB, Largaespada DA, Cooper LJ. A transposon and transposase system for human application. Mol Ther. 18:674–83.Google Scholar
  58. 58.
    Izsvak Z, Hackett PB, Cooper LJ, et al. Translating Sleeping Beauty transposition into cellular therapies: victories and challenges. Bioessays 32:756–67.Google Scholar
  59. 59.
    •• Kalos M, Levine BL, Porter DL, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3:95ra73. Trial showing impressive clinical activity in 3 patients with relapsed/refractory chronic lymphocytic leukemia who received treatment with chimeric antigen receptor modified T cells.PubMedCrossRefGoogle Scholar
  60. 60.
    •• Porter DL, Levine BL, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33. Study showing long-term persistence of engineered T cells in-vivo.PubMedCrossRefGoogle Scholar
  61. 61.
    • Brentjens R, Yeh R, Bernal Y, et al. Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial. Mol Ther. 2010;18:666–8. Unforseen adverse event in a patient treated with genetically engineered T-cells.PubMedCrossRefGoogle Scholar
  62. 62.
    Brentjens RJ, Riviere I, Park JH, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–28.PubMedCrossRefGoogle Scholar
  63. 63.
    Kochenderfer JN, Wilson WH, Janik JE, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116:4099–102.PubMedCrossRefGoogle Scholar
  64. 64.
    Cooper LJ, Jena B, Bollard CM. Good T cells for bad B cells. Blood. 2012;119:2700–2.PubMedCrossRefGoogle Scholar
  65. 65.
    Kochenderfer JN, Dudley ME, Feldman SA, et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012;119:2709–20.PubMedCrossRefGoogle Scholar
  66. 66.
    Jensen MC, Popplewell L, Cooper LJ, et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant. 2010;16:1245–56.PubMedCrossRefGoogle Scholar
  67. 67.
    Savoldo B, Ramos CA, Liu E, et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest. 2011;121:1822–6.PubMedCrossRefGoogle Scholar
  68. 68.
    Kebriaei P, Huls H, Jena B, et al. Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies. Hum Gene Ther. 2012;23:444–50.PubMedCrossRefGoogle Scholar
  69. 69.
    Till BG, Jensen MC, Wang J, et al. CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. 2012;119:3940–50.PubMedCrossRefGoogle Scholar
  70. 70.
    Vera J, Savoldo B, Vigouroux S, et al. T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood. 2006;108:3890–7.PubMedCrossRefGoogle Scholar
  71. 71.
    Giordano Attianese GM, Marin V, Hoyos V, et al. In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor. Blood. 2011;117:4736–45.Google Scholar
  72. 72.
    Zhang S, Chen L, Cui B, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7:e31127.PubMedCrossRefGoogle Scholar
  73. 73.
    Yamaguchi T, Yanagisawa K, Sugiyama R, et al. NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma. Cancer Cell. 2012;21:348–61.PubMedCrossRefGoogle Scholar
  74. 74.
    Kochenderfer JN, AffiliationsNational Cancer Institute B, MD, MED, et al. Dramatic Regression of Chronic Lymphocytic Leukemia in the First Patient Treated With Donor-Derived Genetically-Engineered Anti-CD19-Chimeric-Antigen-Receptor-Expressing T Cells After Allogeneic Hematopoietic Stem Cell Transplantation. BBMT. 2011;17:S158.Google Scholar
  75. 75.
    Bollard C, Cruz C, Savoldo B, et al. Outcomes of CD19-directed multivirus specific cytotoxic T lymphocyte therapy for patients with relapsed B cell malignancies after allogeneic haematopoietic stem cell transplantation. Bone Marrow Transplantation. 2012;47:S56.Google Scholar
  76. 76.
    Gattinoni L, Lugli E, Ji Y, et al. A human memory T cell subset with stem cell-like properties. Nat Med. 2011;17:1290–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Berger C, Berger M, Anderson D, et al.: A non-human primate model for analysis of safety, persistence, and function of adoptively transferred T cells. J Med Primatol.Google Scholar
  78. 78.
    Hinrichs CS, Borman ZA, Cassard L, et al. Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity. Proc Natl Acad Sci U S A. 2009;106:17469–74.PubMedCrossRefGoogle Scholar
  79. 79.
    Rossig C, Bollard CM, Nuchtern JG, et al. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy. Blood. 2002;99:2009–16.PubMedCrossRefGoogle Scholar
  80. 80.
    Cooper LJ, Al-Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105:1622–31.PubMedCrossRefGoogle Scholar
  81. 81.
    Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13:1440–9.PubMedCrossRefGoogle Scholar
  82. 82.
    Pule MA, Straathof KC, Dotti G, et al. A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. 2005;12:933–41.PubMedCrossRefGoogle Scholar
  83. 83.
    Lamers CH, Willemsen R, van Elzakker P, et al. Immune responses to transgene and retroviral vector in patients treated with ex vivo engineered T cells. Blood 2010.Google Scholar
  84. 84.
    Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006;12:6106–15.PubMedCrossRefGoogle Scholar
  85. 85.
    Cui Y, Zhang H, Meadors J, et al. Harnessing the physiology of lymphopenia to support adoptive immunotherapy in lymphoreplete hosts. Blood. 2009;114:3831–40.PubMedCrossRefGoogle Scholar
  86. 86.
    Pegram HJ, Lee JC, Hayman EG, et al. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood. 2012;119:4133–41.PubMedCrossRefGoogle Scholar
  87. 87.
    Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24:1160–70.PubMedCrossRefGoogle Scholar
  88. 88.
    P.R. Manuri SO, N. Dara, M.J. Dawson, H. Huls, D.A. Lee, E.J. Shpall, R.E. Champlin, L.J.N. Cooper: A fully-human chimeric antigen receptor for redirecting specificity of T cells to B-lineage tumors American Society for Blood and Marrow Transplantation, Tandem Meetings. San Diego, California, 2008, pp 13–14Google Scholar
  89. 89.
    Willemsen RA, Debets R, Hart E, et al. A phage display selected fab fragment with MHC class I-restricted specificity for MAGE-A1 allows for retargeting of primary human T lymphocytes. Gene Ther. 2001;8:1601–8.PubMedCrossRefGoogle Scholar
  90. 90.
    Palendira U, Chinn R, Raza W, et al. Selective accumulation of virus-specific CD8+ T cells with unique homing phenotype within the human bone marrow. Blood. 2008;112:3293–302.PubMedCrossRefGoogle Scholar
  91. 91.
    Brown CE, Vishwanath RP, Aguilar B, et al. Tumor-derived chemokine MCP-1/CCL2 is sufficient for mediating tumor tropism of adoptively transferred T cells. J Immunol. 2007;179:3332–41.PubMedGoogle Scholar
  92. 92.
    June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest. 2007;117:1466–76.PubMedCrossRefGoogle Scholar
  93. 93.
    Morgan RA, Dudley ME, Wunderlich JR, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314:126–9.PubMedCrossRefGoogle Scholar
  94. 94.
    Lamers CH, Sleijfer S, Vulto AG, et al. Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience. J Clin Oncol. 2006;24:e20–2.PubMedCrossRefGoogle Scholar
  95. 95.
    Morgan RA, Yang JC, Kitano M, et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 18:843–51.Google Scholar
  96. 96.
    Hacein-Bey-Abina S, Garrigue A, Wang GP, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118:3132–42.PubMedCrossRefGoogle Scholar
  97. 97.
    Baum C, Kustikova O, Modlich U, et al. Mutagenesis and oncogenesis by chromosomal insertion of gene transfer vectors. Hum Gene Ther. 2006;17:253–63.PubMedCrossRefGoogle Scholar
  98. 98.
    Bonini C, Grez M, Traversari C, et al. Safety of retroviral gene marking with a truncated NGF receptor. Nat Med. 2003;9:367–9.PubMedCrossRefGoogle Scholar
  99. 99.
    Choi Y, Yuen C, Maiti SN, et al. A high throughput microelectroporation device to introduce a chimeric antigen receptor to redirect the specificity of human T cells. Biomed Microdevices 12:855–63.Google Scholar
  100. 100.
    Hoyos V, Savoldo B, Quintarelli C, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 24:1160–70.Google Scholar
  101. 101.
    James SE, Orgun NN, Tedder TF, et al. Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice. Blood. 2009;114:5454–63.PubMedCrossRefGoogle Scholar
  102. 102.
    Singh H, Serrano LM, Pfeiffer T, et al. Combining adoptive cellular and immunocytokine therapies to improve treatment of B-lineage malignancy. Cancer Res. 2007;67:2872–80.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Chitra Hosing
    • 1
  • Partow Kebriaei
    • 1
  • William Wierda
    • 2
  • Bipulendu Jena
    • 3
  • Laurence J. N. Cooper
    • 3
  • Elizabeth Shpall
    • 1
  1. 1.Department of Stem Cell TransplantationUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Department of LeukemiaUniversity of Texas MD Anderson Cancer CenterHoustonUSA
  3. 3.Division of PediatricsUniversity of Texas MD Anderson Cancer CenterHoustonUSA

Personalised recommendations